Fecal calprotectin in ileal Crohn's disease: Relationship with magnetic resonance enterography and a pathology score

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1572-1579

  Cerrillo, Elena ^a   Beltrán, Belén ^a,b   Pous, Salvador ^a   Echarri, Ana ^c   Gallego, Jose Carlos ^c   Iborra, Marisa ^a,b   Pamies, Jose ^a   Nos, Pilar ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Universidad de La Coruña   (Spain)

Author keywords

fecal calprotectin; magnetic resonance enterography; small bowel Crohn's disease; surgical pathology

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; FECAL CALPROTECTIN; GADOBENATE DIMEGLUMINE; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; SCOPOLAMINE BUTYL BROMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHIOREAN INDEX; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY ASSESSMENT; ELISA READER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HARVEY BRADSHAW INDEX; HISTOLOGY; HUMAN; HUMAN TISSUE; ILEAL CROHN DISEASE; ILEUM DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE EXAMINATION; INTESTINE SURGERY; MAGNETIC RESONANCE ENTEROGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SECONDARY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURGICAL PATHOLOGY; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; COLONOSCOPY; FECES; ILEUM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; COLONOSCOPY; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; ILEUM; LEUKOCYTE L1 ANTIGEN COMPLEX; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84932131823     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000404     Document Type: Article

References (28)

1. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556-585.
2. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.
3. Fletcher JG, Fidler JL, Bruining DH, et al. New concepts in intestinal imaging for inflammatory bowel diseases. Gastroenterology. 2011;140: 1795-1806.
4. Mazziotti S, Ascenti G, Scribano E, et al. Guide to magnetic resonance in Crohn's disease: from common findings to the more rare complicances. Inflamm Bowel Dis. 2011;17:1209-1222.
5. Hyun SB, Kitazume Y, Nagahori M, et al. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease. Inflamm Bowel Dis. 2011;17: 1063-1072.
6. Oussalah A, Laurent V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010;59:1056-1065.
7. Rimola J, Rodriguez S, Garcia BO, et al. Magnetic resonance for assessment of disease activity and severity in Crohn's disease. Gut. 2009;58: 1113-1120.
8. Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17: 1759-1768.
9. DHaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
10. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
11. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8: 197-210.
12. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-Analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
13. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.
14. Ordas I, Rimola J, Rodriguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology. 2014;146:374-382.
15. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
16. Zippi M, Al Ansari N, Siliquini F, et al. Correlation between faecal calprotectin and magnetic resonance imaging (MRI) in the evaluation of inflammatory pattern in Crohn's disease. Clin Ter. 2010;161:e53-e56.
17. Parisinos CA, McIntyre VE, Heron T, et al. Magnetic resonance followthrough imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis. 2010;16: 1219-1226.
18. Makanyanga JC, Pendse D, Dikaios N, et al. Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol. 2014;24:277-287.
19. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7-27.
20. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
21. Vermiere S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
22. Chiorean MV, Sandrasegaran K, Saxena R, et al. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol. 2007;102:2541-2550.
23. Pupillo VA, Di Cesare E, Frieri G, et al. Assessment of inflammatory activity in Crohn's disease by means of dynamic contrast-enhanced MRI. Radiol Med. 2007;112:798-809.
24. Giusti S, Faggioni L, Neri E, et al. Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and timesignal intensity curves for differentiating between active and inactive Crohn's disease. Abdom Imaging. 2010;35:646-653.
25. Domenech JM, Granero R. Macro! ROC for SPSS Statistics. Roc Analysis [computer Program]. V2010.02.04. Bellaterra, Spain: Universitat Autonoma de Barcelona; 2010.
26. Van Assche G, Herrmann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis. 2013;7:950-957.
27. Novak KL, Panaccione R. Will cross-sectional imaging replace endoscopy for monitoring response to therapy in Crohn's disease?. Gastroenterology. 2014;146:334-336.
28. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol. 2014;12:253-262.